NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 115 filers reported holding NURIX THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $151,258 | -21.3% | 19,244 | 0.0% | 0.00% | – |
| Q2 2023 | $192,248 | +19.1% | 19,244 | +5.9% | 0.00% | – |
| Q1 2023 | $161,385 | -76.0% | 18,174 | -70.4% | 0.00% | – |
| Q4 2022 | $671,765 | -14.6% | 61,338 | +0.8% | 0.00% | -100.0% |
| Q3 2022 | $786,924 | +2.1% | 60,857 | -0.8% | 0.00% | 0.0% |
| Q2 2022 | $770,398 | -18.3% | 61,350 | -8.0% | 0.00% | 0.0% |
| Q1 2022 | $942,996 | +93.6% | 66,700 | +307.2% | 0.00% | – |
| Q4 2021 | $487,000 | -1.2% | 16,382 | -0.4% | 0.00% | – |
| Q3 2021 | $493,000 | +4.2% | 16,445 | -7.7% | 0.00% | – |
| Q2 2021 | $473,000 | +14.3% | 17,820 | +33.9% | 0.00% | – |
| Q1 2021 | $414,000 | +79.2% | 13,310 | +89.6% | 0.00% | – |
| Q4 2020 | $231,000 | +11.6% | 7,020 | +18.3% | 0.00% | – |
| Q3 2020 | $207,000 | – | 5,935 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |